Relationship between metabolic enzyme polymorphism and colorectal cancer

doi:10.3748/wjg.v11.i3.331

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 3

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3009)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

286

HTML

2468

Figures (1-2)

126

Tables (1-3)

129

Sum=3009

Jan 21, 2005 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (56)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Colorectal Cancer

World J Gastroenterol. Jan 21, 2005; 11(3): 331-335
Published online Jan 21, 2005. doi: 10.3748/wjg.v11.i3.331

Table 1 References to colorectal cancer and polymorphisms of metabolic enzymes.

References	Gene and polymor-phism¹	Grouping²	References	Gene and polymor-phism¹	Grouping²
Carcinogenesis. 1991; 12(1): 25-8	1	B	Pharmacogenetics. 1999; 9(2): 165-9	6	B
Carcinogenesis. 1993; 14(9): 1821-4 (abstract)	1	B	Cancer-Res 1995; 55(16): 3537-42	3	B
Carcinogenesis. 1995; 16(7): 1655-7 (abstract)	1,2		Am-J-Epi 1997;145 (abstract)	4
Carcinogenesis. 1996; 17(4): 881-4	1,2	B	Cancer-Res. 1998; 58(15): 3307-11	3,5	B
Carcinogenesis. 1996; 17(9): 1855-9	1,2	B	Int-J-Cancer. 1990; 46(1): 22-30	4	B
Carcino-Terato-Muta 1996; 8(6): 326-332	1	B	Cancer-Res. 1991; 51(8): 2098-100	4	B
Can-Epi-Bio-Prev. 1998; 7(11): 1001-5	1,2	B	Can-Epi-Bio-Prev. 1994; 3(8): 675-82	4
J-Toxicol-Sci. 1998; 23 Suppl 2140-2 (abstract)	1		Cancer. 1994; 74(12): 3108-12	4	B
Can-Epi-Bio-Prev. 1998; 7(12): 1079-84 (abstract)	1,5		Lancet. 1996; 347(9012): 1372-4	4
Zhengjiang Yixueyuan Xuebao 1998; 8(4): 446-447	1	B	Cancer res on prevention and treatment	4	B
			1999; 26(3): 232-233
Cancer-Epidemiol-Biomarkers-Prev. 1999; 8(1): 15-24	1,4	B	Gut. 1997; 41(2): 229-34	5	B
Cancer-Lett. 1999; 142(1): 97-104	1,2	B	Carcinogenesis. 1997l; 18(7): 1351-4	5	B
Exp-Toxicol-Pathol. 1999; 51(4-5): 321-5 (abstract)	1		Carcinogenesis. 1998; 19(1): 37-41	5	B
Can-Epi-Bio-Prev. 1999; 8(4 Pt 1): 289-92	1,2,6	B	Pharmacogenetics. 1998; 8(6): 513-7	5
J-UOEH. 1999; 21(2): 133-47	1,2,3,5,6	B	Cancer-Res. 1996; 56(21): 4862-4	9	B
Jiangshu Linchuangyixue Zazhi 2000; 4(2): 90-91	1,2	B	Cancer-Res. 1997; 57(6): 1098-102	9	B
Anticancer-Res. 2000; 20(1B): 519-22 (abstract)	1		Genet-Test. 1999; 3(2): 233-6	9	B
J-Gast-Hepatol. 2001; 16(6): 631-5 (abstract)	2		Can-Epi-Bio-Prev. 1999; 8(6): 513-8	9
Carcinogenesis. 2001; 22(7): 1053-60	1,2,5,6	B	Can-Epi-Bio-Prev. 1999; 8(9): 825-9	10	B
Gastroenterology 1997: 112: A542 (abstract)	2	B	Can-Epi-Bios-Prev. 2000 ; 9(8): 855-6	7,8	B
			Carcinogenesis. 2001; 88(8): 1323-6	7,8	B

¹Note: 1-GSTM1 deletion, 2-GSTT1 deletion, 3-NAT1*10, 4-NAT2-rapid acetylator phenotype, 5-NAT2-rapid acetylator genotype, 6-GSTP1 lle105Val, 7-CYP1A1 Lle462Val, 8-CYP1A1 MspI*C, 9-METHFR C677T, 10-MTR A2759G

²Note, Grouping B: The literatures in group B, grouping A: The literatures in group B.

Table 2 Results of meta-analysis of polymorphisms and risk for colorectal cancer in group A.

	Study numbers	Cumulative cases	Cumulative controls	Test of heterogeneity		Statistical method	OR	95% CI	Significance P
	Study numbers	Cumulative cases	Cumulative controls	Q	P		OR	95% CI	Significance P
GSTM1 deletion	18	5455	6853	31.1	<0.05	Statistical method	Random	1.08	0.96-1.20	>0.20
GSTT1 deletion	11	1348	1792	29.79	<0.001	Random	1.42^b	1.21-1.66	<0.001
GSTP1 lle105Val	4	612	755	4.06	0.2	Fixed	1.09	0.87-1.37	>0.30
NAT1*10	3	520	433	5.43	0.10-0.20	Fixed	1.25	0.96-1.63	>0.10
NAT2-rapid acetylator p&g	18	6741	8015	22.86	0.20-0.30	Fixed	1.08^a	1.00-1.16	<0.05
NAT2-rapid acetylator p	8	2182	2861	14.24	0.10-0.20	Fixed	1.15^a	1.02-1.31	<0.05
NAT2-rapid acetylator g	10	4559	5154	7.71	>0.50	Fixed	1.05	0.94-1.14	>0.20
CYP1A1 Lle462Val	2	235	280	1.77	>0.30	Fixed	1.26	0.77-2.08	0.05-0.1
CYP1A1 MspI*C	2	234	250	8.36	<0.02	Random	1.3	0.82-2.06	>0.30
METHFR C677T	4	1949	3099	3.11	0.30-0.50	Fixed	0.83	0.68-1.01	>0.10
MTR A2759G	3	613	1 189	0	0.9	Fixed	0.6	0.28-1.29	0.10-0.20

Fixed: Fixed-effect model, Random: Random-effects model.

^aP<0.05,

^bP<0.01.

Table 3 Results of meta-analysis of polymorphisms and risk for colorectal cancer in group B.

Gene and polymorphism	Study numbers	Cumulative cases	Cumulative controls	Test of heterogeneity		Statistical method	OR	95% CI	Significance P
Gene and polymorphism	Study numbers	Cumulative cases	Cumulative controls	χ	P		OR	95% CI	Significance P
GSTM1 deletion	14	3002	3911	20.54	0.08	Statistical method	Fixed	1.07	0.97-1.17	0.2
GSTT1 deletion	8	1029	1492	12.52	0.085	Fixed	1.20^a	1.00-1.44	0.05
GSTP1 lle105Val	4	609	755	3.63	0.3	Fixed	1.08	0.86-1.35	0.5
NAT1*10	3	520	433	5.2	0.07	Fixed	1.2	0.92-1.56	0.18
NAT2-rapid acetylator p&g	12	3121	3697	13.61	0.26	Fixed	1.02	0.92-1.13	0.7
NAT2-rapid acetylator p	6	2038	2546	8.91	0.11	Fixed	1.06	0.94-1.20	0.3
NAT2-rapid acetylator g	6	1083	1151	3.62	0.61	Fixed	0.95	0.79-1.13	0.5
CYP1A1 Lle462Val	2	235	280	1.62	0.2	Fixed	1.17	0.71-1.91	0.5
CYP1A1 MspI*C	2	234	280	5.01	0.03	Random	1.21	0.77-1.90	0.4
METHFR C677T	3	546	1 413	1.38	0.5	Fixed	0.69^a	0.51-0.94	0.02
MTR A2759G	2	356	476	0	0.98	Fixed	0.6	0.28-1.29	0.19

Fixed: Fixed-effect model, Random: Random-effects model.

^aP<0.05.

Citation: Chen K, Jiang QT, He HQ. Relationship between metabolic enzyme polymorphism and colorectal cancer. World J Gastroenterol 2005; 11(3): 331-335
URL: https://www.wjgnet.com/1007-9327/full/v11/i3/331.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i3.331